INmune Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2016
Net Income	-34.5	-30.01	-27.3	-30.34	-12.1	-7.68	Upgrade
Share-Based Compensation	7.41	7.37	7.15	4.8	3.11	4.1	Upgrade
Other Operating Activities	8.77	10.66	-2.54	-2.96	0.04	-1.8	Upgrade
Operating Cash Flow	-18.32	-11.98	-22.69	-28.5	-8.94	-5.38	Upgrade
Acquisitions	0	0	0	-15	0	0	Upgrade
Investing Cash Flow	0	0	0	-15	0	0	Upgrade
Share Issuance / Repurchase	0.78	0.78	0.73	81.41	23.9	12.21	Upgrade
Debt Issued / Paid	-7.5	-5	0	14.95	0	0	Upgrade
Financing Cash Flow	-6.73	-4.23	0.73	96.36	23.9	12.21	Upgrade
Exchange Rate Effect	0.04	-0.1	-0.7	-0.01	0.02	-0.02	Upgrade
Net Cash Flow	-25	-16.31	-22.66	52.84	14.97	6.81	Upgrade
Free Cash Flow	-18.32	-11.98	-22.69	-28.5	-8.94	-5.38	Upgrade
Free Cash Flow Margin	-13980.92%	-7729.03%	-6065.78%	-15748.07%	-81300.00%	-	Upgrade
Free Cash Flow Per Share	-1.02	-0.67	-1.26	-1.77	-0.75	-0.52	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).